Panoprist (Perindopril Tert-Butylamine, Indapamide)

Perindopril arginine blocks the angiotensin‑converting enzyme, decreasing the formation of angiotensin II, a powerful vasoconstrictor. The resulting vasodilation, reduced aldosterone release and lower sodium‑water retention collectively lower arterial pressure and ease cardiac strain.

The prescribed dose of Panoprist is individualized by the treating physician based on the patient’s condition, blood‑pressure targets and renal function. Dosage adjustments are made according to clinical response and tolerability.

Perindopril is contraindicated in the second and third trimesters of pregnancy because of risk to the fetus. Limited data exist for breastfeeding; therefore, use is generally discouraged unless the benefit outweighs potential risk.

To request Panoprist, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and necessary import documentation.

Panoprist (perindopril) offers a long‑acting antihypertensive effect with a favourable side‑effect profile compared with some ACE‑inhibitors that may cause more frequent cough. Clinical studies show comparable blood‑pressure reductions to enalapril and ramipril, with added benefits in heart‑failure outcomes.

Panoprist tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Panoprist is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events include angioedema, severe hypotension, acute kidney injury and hyperkalaemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, a sudden drop in blood pressure, or signs of renal dysfunction.

Panoprist is contraindicated in patients with a history of angioedema related to ACE‑inhibitors, those in the second or third trimester of pregnancy, and individuals with severe renal impairment unless closely monitored. Caution is also advised for patients taking potassium‑sparing diuretics or supplements.